News

nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman

The Boston-based biotech veteran will lead the business, which specializes in nucleic acid based medicines Granada,...

Read more

Oligonucleotide Therapeutics and Delivery conference at Boston to host nLife talk on April 5, 2016

Leading drug developers and discovery scientists will gather to discuss technological and scientific advances at the upcoming Oligonucleotide Therapeutics...

Read more

nLife Therapeutics receives USD 350,000 from The Michael J. Fox Foundation for Parkinson’s Research

nLife Therapeutics receives USD 350,000 from The Michael J. Fox Foundation for Parkinson’s Research The funding will...

Read more
Cabecera
 
Parkinson
Alzheimer
Huntington

Neuronal-focused Therapies
for a Healthy Life

nLife Therapeutics

  • nLife Therapeutics is a biopharmaceutical company leading the discovery and development of cell specific oligonucleotides as therapeutic agents for Central Nervous System and Neuromuscular disorders
  • nLife Therapeutics provides a unique oligonucleotide delivery platform with strong IP protection enabling precision medicine from “gene silencing” to “non-viral gene therapy”
  • Preclinical data validate technology for a disease modifying therapy for Parkinson’s disease (PD) in rodents and non human primates
  • Technology potentially applies to a broad array of genetic disorders
 
Pipeline
Platform
 
Ministerio de Ciencia e Innovación: MICINN
Ministerio de Industria y Competitividad: MINECO
Centro para el Desarrollo Tecnológico e Industiral: CDTI
Unión Europea con el emblema de FEDER
Xunta de Galicia
Michael J. Fox Foundation